| Identification | Back Directory | [Name]
2H,6H,10H-Benzo[1,2-e:3,4-e':5,6-e'']tris[1,3]oxazine, 3,4,7,8,11,12-hexahydro-3,7,11-tris(phenylmethyl)- (9CI) | [CAS]
6638-82-0 | [Synonyms]
2H,6H,10H-Benzo[1,2-e:3,4-e':5,6-e'']tris[1,3]oxazine, 3,4,7,8,11,12-hexahydro-3,7,11-tris(phenylmethyl)- (9CI) | [Molecular Formula]
C33H33N3O3 | [MOL File]
6638-82-0.mol | [Molecular Weight]
519.63 |
| Chemical Properties | Back Directory | [Melting point ]
162-163 °C(Solv: benzene (71-43-2); ethanol (64-17-5)(9:1)) | [Boiling point ]
642.4±55.0 °C(Predicted) | [density ]
1.263±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
5.08±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia[1]. | [in vivo]
SGF29-IN-1 (5 mg/kg, i.p. every other day for 35 days) inhibits leukemia progression without significant toxicity in CD45 mice[1]. | Animal Model: | MLL-AF9 xenograft CD45 mice[1] | | Dosage: | 5 mg/kg | | Administration: | i.p., every other day for 35 days | | Result: | Reduced percentage of 45.2 cells in peripheral blood and spleen. Improved survival rate of rats. |
| [References]
[1] Chan AKN, et al., Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery. Sci Adv. 2024 Feb 23;10(8):eadk3127. DOI:10.1126/sciadv.adk3127 |
|
|